NeuroSense Therapeutics Ltd.NRSN
Price (close)
$7.40
Market cap
$14.0M
P/E
—
Revenue (FY)
—
Net income
-$11.1M
Dividend yield
—
1-year total return
527.1%
Net margin
—
Revenue growth
—
Debt / equity
—
What NeuroSense Therapeutics Ltd. does.
are a clinical-stage biotechnology company focused on discovering and developing treatments for people living with neurodegenerative
diseases, including ALS, AD and PD. We believe these diseases represent some of the most significant unmet medical needs of our time,
with limited effective therapeutic options available. The burden of these diseases on both patients and society is substantial. For example,
Revenue and profit, by fiscal year.
| Fiscal year | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Net income | -$2.8M | -$4.0M | -$10.5M | -$10.1M | -$10.2M | -$11.1M |
| Free cash flow | -$704,000 | -$1.6M | -$7.7M | -$8.4M | -$10.1M | -$7.7M |
More on NRSN.
- NeuroSense Therapeutics Ltd. summary
- NeuroSense Therapeutics Ltd. financial statements
- NeuroSense Therapeutics Ltd. key metrics
- NeuroSense Therapeutics Ltd. health scores and style box
- NeuroSense Therapeutics Ltd. earnings
- NeuroSense Therapeutics Ltd. dividends
- NeuroSense Therapeutics Ltd. valuation
- NeuroSense Therapeutics Ltd. ownership and insiders
- NeuroSense Therapeutics Ltd. peers
Figures from NeuroSense Therapeutics Ltd.'s filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.